OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.
OnCusp Therapeutics has raised $100.0M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
OnCusp Therapeutics's investors include HSG, Blackbird Ventures, Catalio Capital Management, OrbiMed, F-Prime Capital.
OnCusp Therapeutics is headquartered in New York, United States.
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.
OnCusp Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OnCusp Therapeutics — Funding & Investors." VCBacked, January 4, 2024, https://www.vcbacked.co/company/oncusp-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). OnCusp Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/oncusp-therapeutics
{{cite web |title=OnCusp Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/oncusp-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated